Results 21 to 30 of about 3,649,731 (302)

EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]

, 2013
EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal, Adams, Bailey, Bailey, Basu, Bibby, Bibby, Burd, Butler, Cadenas, Ceelen, Choudry, Collard, Connors, Cowan, Cummings, Denny, Dirix, Ernster, Fitzsimmons, Gofrit, Hall, Hargreaves, Hay, Hay, Hay, Hendricksen, Hendricksen, Hendriks, Jain, Loadman, Lu, Maliepaard, Masters, Masters, McKeown, McLeod, Milbank, Minchinton, Oostveen, Pavlidis, Phillips, Phillips, Phillips, Phillips, Phillips, Phillips, Pizao, Plumb, Plumb, Plumb, Puri, Rademakers, Robertson, Robertson, Roed, Schellens, Segura-Aguilar, Siegel, Siegel, Smitskamp-Wilms, Stratford, Sylvester, Tercel, van der Heijden, van der Schoot, van der Schoot, van der Schoot, Vaupel, Vaupel, Walton, Walton, Workman, Workman, Workman, Zappa   +75 more
core   +1 more source

Tanshinone ΙΙA-Incubated Mesenchymal Stem Cells Inhibit Lipopolysaccharide-Induced Inflammation of N9 Cells through TREM2 Signaling Pathway

Stem Cells International, 2022
Our previous study found that incubating mesenchymal stem cells (MSC) with tanshinone IIA (TIIA) before transplantation could significantly increase the inhibitory effect of MSC on neuroinflammation.
Nanqu Huang, Juan Huang, Fei Feng, Zhisheng Ba, Yuanyuan Li, Yong Luo   +5 more
doaj   +1 more source

Safety and Tolerability of an Antimalarial Herbal Remedy in Healthy Volunteers: An Open-Label, Single-Arm, Dose-Escalation Study on Maytenus senegalensis in Tanzania

Tropical Medicine and Infectious Disease, 2022
Background: Though Maytenus senegalensis is one of the medicinal plants widely used in traditional medicine to treat infectious and inflammatory diseases in Africa, there is a lack of safety data regarding its use.
Kamaka Kassimu, Florence Milando, Justin Omolo, Abel Mdemu, Gloria Nyaulingo, Hussein Mbarak, Latipha Mohamed, Ramla Rashid, Saumu Ahmed, Mohammed Rashid, Hania Msami, David Damiano, Beatus Simon, Thabit Mbaga, Fatuma Issa, Omar Lweno, Neema Balige, Omary Hassan, Bakari Mwalimu, Ali Hamad, Ally Olotu, Andreas Mårtensson, Francis Machumi, Said Jongo, Billy Ngasala, Salim Abdulla   +25 more
doaj   +1 more source

Prototype of running clinical trials in an untrustworthy environment using blockchain. [PDF]

, 2019
Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system.
Bhattacharya, Sanchita, Butte, Atul J, Wong, Daniel R   +2 more
core   +3 more sources

The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. [PDF]

, 2020
This commentary introduces a new clinical trial construct, the Master Observational Trial (MOT), which hybridizes the power of molecularly based master interventional protocols with the breadth of real-world data.
Bergan, Raymond, Dickson, Dane, Johnson, Jennifer, Kurzrock, Razelle, Owens, Rebecca, Subbiah, Vivek   +5 more
core  

Using the TIDieR checklist to standardize the description of a functional strength training intervention for the upper limb after stroke [PDF]

, 2016
Background and Purpose: Published reports of intervention in randomized controlled trials are often poorly described. The Template for Intervention Description and Replication (TIDieR) checklist has been recently developed to improve the reporting of ...
Donaldson, Catherine, Hunter, Susan M., Pomeroy, Valerie, Van Vliet, Paulette   +3 more
core   +2 more sources

Neuroprotective Properties of Xenon. [PDF]

, 2020
Xenon is a rare noble gas that was introduced into clinical practice more than 70 years ago. Xenon's clinical properties are predicated by its ability to fit into preformed cavities of macromolecules thereby altering their biological functions.
Laitio, Timo, Maze, Mervyn
core  

Potential implications of practice effects in Alzheimer's disease prevention trials. [PDF]

, 2017
IntroductionPractice effects (PEs) present a potential confound in clinical trials with cognitive outcomes. A single-blind placebo run-in design, with repeated cognitive outcome assessments before randomization to treatment, can minimize effects of ...
Ard, M Colin, Bondi, Mark W, Edland, Steven D, Galasko, Douglas R, Jacobs, Diane M, Salmon, David P   +5 more
core   +1 more source

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Annals of Medicine, 2022
Background The primary objective of this study was to investigate if hepatic impairment alters the safety, pharmacokinetics, and pharmacodynamics of HSK3486.Research design and methods This was a clinical trial of HSK3486 in subjects with normal hepatic ...
Yue Hu, Xiaojiao Li, Jingrui Liu, Hong Chen, Wenbo Zheng, Hong Zhang, Min Wu, Cuiyun Li, Xiaoxue Zhu, Jinfeng Lou, Pangke Yan, Nan Wu, Xiao Liu, Shiping Ma, Xu Wang, Yanhua Ding, Chengluan Xuan   +16 more
doaj   +1 more source

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source